Core Viewpoint - Hologic, Inc. plans to release its financial results for the first quarter of fiscal 2026 on January 29, after market close, and will not host a quarterly conference call or provide financial guidance due to its pending acquisition by Blackstone and TPG [1]. Company Overview - Hologic, Inc. is an innovative medical technology company focused on improving women's health and well-being through early detection and treatment [2].

Financial Data and Key Metrics Changes - The company reported an adjusted EPS of $1.81 and an adjusted ROTCE of 7.7% for Q4 2025, with full-year adjusted net income surpassing $16 billion, reflecting an 180 basis points improvement to 8.8% ROTCE [4][20] - Total revenues increased by 2%, with adjusted revenues up 8%, driven by growth in banking, services, US Personal Banking (USPB), and Wealth [19][20] - Expenses rose by 6% to $13.8 billion, influenced by higher compensation, tax charges, and technology expenses [19][22] Business Line Data and Key Metrics Changes - Services revenues increased by 15%, with net income of $2.2 billion and an ROTCE of 36.1% for Q4 [27][28] - Markets revenues were down 1%, with fixed income and equities both experiencing slight declines, but overall, the Markets business saw an 11% revenue increase for the full year [30][31] - Banking revenues surged by 78%, driven by corporate lending and investment banking, with M&A fees up 84% [31][32] - Wealth management revenues grew by 7%, with net new investment asset flows of $7.2 billion in Q4 [32][34] Market Data and Key Metrics Changes - The company reported a 24% increase in assets under custody and administration, reflecting strong client engagement and onboarding of new clients [5][28] - Cross-border transaction value increased by 14%, indicating robust activity in the services sector [28] - The corporate exposure remains primarily investment-grade, with low corporate non-accrual loans and net credit losses [25] Company Strategy and Development Direction - The company is focused on a multi-year transformation journey, emphasizing operational efficiency, technology investments, and enhancing client experience through AI [4][12] - The strategy includes maintaining a disciplined approach to expenses while investing in growth areas, aiming for a ROTCE target of 10%-11% [15][39] - The company is actively working to close the gap with best-in-class peers in investment banking and capital markets through talent acquisition and product innovation [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the global economic outlook, citing strong capital investment and a healthy consumer environment as drivers for growth [12][14] - The company is well-positioned to navigate challenges, with a focus on leveraging its balance sheet and expertise across nearly 100 countries [14] - Management highlighted the importance of continued investment in the franchise to sustain growth and improve returns [39][76] Other Important Information - The company repurchased over $13 billion in common shares during the year, with a CET1 ratio of 13.2%, significantly above regulatory requirements [10][26] - The company is nearing the end of its international divestitures, with significant progress in its transformation efforts [11][39] Q&A Session Summary Question: Insights on Markets performance and ROTCE - The fourth quarter had tough year-over-year comparisons, but the full year saw strong performance in Markets, particularly in spread products and equities [50][52] Question: Efficiency ratio target clarification - The efficiency ratio target was adjusted to around 60% to allow for continued investments in the business while maintaining expense discipline [54][55] Question: Transformation progress and remaining work - Over 80% of transformation efforts are at or near target state, with remaining work focused on compliance, risk, controls, and data [58][60] Question: Addressing the gap with peers in investment banking - The company is investing in technology and talent to close the gap with best-in-class peers, particularly in investment banking and capital markets [72][76] Question: NII outlook and drivers - The NII outlook for 2026 is expected to grow by 5%-6%, driven by loan and deposit volume growth [89][90]

Financial Data and Key Metrics Changes - The company reported an adjusted EPS of $1.81 and an adjusted ROTCE of 7.7% for Q4 2025, with full-year adjusted net income surpassing $16 billion, reflecting an 180 basis points improvement to 8.8% ROTCE after adjustments for Banamex and Russia [3][18] - Total revenues increased by 2%, with adjusted revenues up 8%, driven by growth in banking, services, USPB, and wealth [17][18] - Expenses rose by 6% to $13.8 billion, influenced by higher compensation, tax charges, and technology expenses [17][20] Business Line Data and Key Metrics Changes - Services revenues increased by 15%, with net income of $2.2 billion and an ROTCE of 36.1% for Q4 [25] - Markets revenues were down 1%, with fixed income and equities both experiencing slight declines, but average loans increased by 25% [27] - Banking revenues surged by 78%, with M&A fees up 84%, marking a record year for investment banking [28][29] - Wealth management revenues grew by 7%, with net new investment asset flows of $7.2 billion in Q4 [30][31] Market Data and Key Metrics Changes - Cross-border transaction value increased by 14%, and assets under custody and administration grew by 24% [25] - The company maintained a diversified deposit base of $1.4 trillion, with a 1% increase driven by growth in services [24] Company Strategy and Development Direction - The company is focused on a multi-year transformation strategy, with over 80% of its programs nearing target state [10][12] - Investments in technology and operational efficiency are prioritized to enhance client experience and reduce expenses [11][39] - The company aims to achieve a ROTCE target of 10%-11% and maintain positive operating leverage [13][36] Management's Comments on Operating Environment and Future Outlook - The global economy is showing signs of optimism, with inflation normalizing and capital investment remaining strong, particularly in technology [11][12] - The company is well-positioned to support corporate clients, who are predominantly investment-grade in credit quality [12] - Management expressed confidence in the ongoing transformation and the ability to deliver higher returns in the future [39] Other Important Information - The company repurchased over $13 billion in common shares during the year, with a total capital return of over $17.5 billion [9][24] - The company is nearing the end of its international divestitures, including the sale of its consumer business in Poland and operations in Russia [9][10] Q&A Session Summary Question: Insights on market performance and ROTCE - Management noted strong top-line revenue growth for markets, with a focus on optimizing RWA and deploying it in high-return areas [41][42][43] Question: Clarification on efficiency ratio targets - Management confirmed the shift in efficiency ratio targets to around 60%, emphasizing the need for continued investment in the business [45] Question: Update on transformation progress - Management highlighted that over 80% of transformation efforts are nearing completion, with a focus on compliance, risk, controls, and data modernization [46][48] Question: Addressing competitive gaps in investment banking - Management acknowledged past gaps but emphasized ongoing investments in technology and talent to enhance competitive positioning [52][54] Question: Outlook for net interest income (NII) - Management expects NII growth of 5%-6% in 2026, driven by loan and deposit volume growth [60][61]

Core Viewpoint - JPMorgan Chase & Co. is providing Altice USA with approximately $1.1 billion to refinance debt, aiming to alleviate creditor concerns following an antitrust lawsuit and controversial debt maneuvers [1]. Group 1: Refinancing Details - The funds from JPMorgan will allow Altice to refinance a $1 billion asset-backed facility obtained from Goldman Sachs and TPG Angelo Gordon in July at par value [2]. - The refinancing is urgent as the debt's call protection period is about to begin, which would require Altice to pay a premium above par for refinancing [2][6]. Group 2: Creditor Relations - Efforts to preserve Altice's cash are expected to appease creditors, as the company has been struggling with a heavy debt load and has engaged advisers to explore options [3]. - Altice's lenders have faced turmoil due to the company's recent actions, including a lawsuit against creditors alleging the formation of an "illegal cartel" [4]. Group 3: Recent Financial Moves - In November, Altice, recently rebranded as Optimum Communications Inc., raised $2 billion from JPMorgan for early refinancing of a loan due in 2028, which had strict investor safeguards [5]. - The refinancing is strategically timed to avoid a premium that could allow lenders to recover up to 116 cents on the dollar [6].

Core Insights - The surge in private equity dealmaking in healthcare was primarily driven by an increase in large deals, despite macroeconomic and policy uncertainties affecting transactions early in 2025 [3][5] - Healthcare private equity deal value reached a record $191 billion in 2025, surpassing previous highs from 2021, with 445 buyouts recorded [8] - The healthcare IT sector saw significant growth, with deal value doubling to approximately $32 billion in 2025, contributing to a 57% year-over-year increase in transactions involving providers and related services [8] Deal Performance - The first quarter of 2025 experienced a 21% increase in the number of deals compared to the same period in 2024 [4] - The largest healthcare private equity deal in 2025 was the acquisition of Hologic by Blackstone and TPG, accounting for about 9% of total healthcare private equity value [5] - IT firms represented nearly 20% of healthcare transactions in 2025, up from 15% in 2021, indicating a growing investor interest in healthcare IT tools [6] Market Outlook - The healthcare private equity sector is expected to remain active in 2026, supported by high levels of dry powder and an increasing number of sponsor-owned assets nearing the end of their fund lives [7]

Core Viewpoint - Goldman Sachs has issued a report on TPG Inc. focusing on its long-term strategic partnership with Jackson Financial, which is expected to provide stable asset management and fee income for TPG, laying a solid foundation for future growth [1] Group 1: Partnership Details - TPG will manage an asset portfolio valued at $12 billion from Jackson Financial, with a diverse investment scope including investment-grade bonds and direct lending, expected to grow to $20 billion over the next five years [1] - In return, Jackson will receive $150 million in TPG stock and TPG will invest $500 million into Jackson [1] Group 2: Financial Projections - By 2028, TPG's free cash flow per share is projected to grow by 1.2% to 2.1%, while diluted earnings per share may see a slight decline of -0.2% to an increase of 1% [2] - The net present value (NPV) from the $20 billion asset is estimated to positively impact TPG's diluted earnings per share by approximately 2% to 3% in 2027 [2] Group 3: Fee Structure and Profitability - TPG will charge at least 50 basis points in management fees from Jackson's assets, with actual rates expected to range between 60 to 75 basis points as direct lending strategies increase [2] - TPG's incremental free cash flow margin is anticipated to remain high at 85% to 100%, benefiting from limited capital investment requirements [2] Group 4: Strategic Alignment and Future Plans - The partnership aligns with TPG's strategy of maintaining a light balance sheet and provides a long-term stable capital source [2] - TPG plans to raise approximately $20 billion in credit funding by 2025, with $8 billion expected in the fourth quarter, further enhancing its credit management fee income [2] Group 5: Investment Outlook - Goldman Sachs maintains a "Buy" rating for TPG with a 12-month target price of $80, based on a comprehensive valuation of TPG's cash flows [3] - The partnership with Jackson Financial is viewed as a significant opportunity for TPG to generate stable income and enhance overall profitability and market competitiveness [3]

Core Viewpoint - Jackson Financial Inc. has formed a long-term strategic partnership with TPG Inc. to capitalize on the establishment of a new captive reinsurer, Hickory Brooke Reinsurance Company, aimed at enhancing Jackson's product offerings and market competitiveness [1][9]. Partnership Details - The partnership combines Jackson's expertise in annuity products and distribution with TPG's private credit platform, aiming to expand Jackson's spread-based product sales and provide flexibility for future insurance solutions [3][5]. - TPG will invest $500 million in Jackson, acquiring approximately 6.5% equity stake, while Jackson will issue 4,715,554 shares at $106.03 per share [7][8]. Investment Management Arrangement - Jackson and TPG have established a non-exclusive investment management arrangement for an initial term of 10 years, with automatic one-year renewals through year 15, enhancing Jackson's investment capabilities [5][6]. - TPG will provide Investment Grade Asset Based Finance and Direct Lending capabilities to complement Jackson's asset management expertise through its subsidiary PPM America, Inc. [5][6]. Capitalization of Hickory Re - The capital from TPG's investment, along with $150 million in excess cash from Jackson, will be utilized to capitalize Hickory Re, which is designed to accelerate sales growth of Jackson's fixed and fixed index annuity products [9]. - The transactions are expected to enhance Jackson's future profitability, general account asset growth, and capital generation, supporting continued growth in free cash flow and capital returns to shareholders [10]. Closing Conditions - The transaction is subject to customary closing conditions and is anticipated to close in the first quarter of 2026 [10].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - TPG is nearing a deal to acquire Optum UK's business from UnitedHealth, with the transaction valued between £1.2 billion and £1.4 billion, and an announcement may come in the next few weeks, although the deal is not finalized and could still fall through [1] Group 1 - The acquisition price for Optum UK is reported to be between £1.2 billion and £1.4 billion [1] - TPG may seek to merge Optum UK with Nextech, a US-based electronic medical records software provider [1] - The deal is expected to be announced in the coming weeks, but it remains subject to finalization [1]

Core Insights - Hologic's Breast Health business has gained significant investor attention, particularly due to a proposed take-private transaction by Blackstone & TPG, which includes a fixed cash offer of $76 per share and a contingent value right (CVR) of up to $3 per share based on revenue metrics for fiscal years 2026 and 2027 [2][9] Business Segments - The Breast Health segment generates revenues from a diverse portfolio, including 3D digital mammography systems and biopsy solutions, with the addition of Endomagnetics in fiscal 2024 contributing $54.9 million in product revenues for fiscal 2025 [3][9] - The Breast Health service business provides recurring revenues through service contracts for the global installed base of gantries, helping to mitigate volatility in capital sales [4][9] Innovation and Technology - Hologic has focused on innovation, introducing FDA-approved technologies such as 3DQuorum Imaging Technology and the next-generation Genius AI Detection PRO software, which reduces radiologists' reading time [5] - The company is advancing contrast-enhanced mammography with I-View 2.0 software and plans to commercially introduce the Envision Mammography Platform, featuring the first FDA-approved mammography focusing technology [5] Competitor Landscape - GE HealthCare has secured a contract to supply over 300 CT scanners in Indonesia, aiming to enhance healthcare access for over 280 million people [6] - Quest Diagnostics and Corewell Health have established a joint venture to expand laboratory services in Michigan, with Quest holding a 51% equity stake [7] Stock Performance and Valuation - Hologic's stock has increased by 11% over the past three months, outperforming the industry growth of 3.7% [8] - The company is trading at a forward five-year price-to-sales (P/S) ratio of 3.83, which is lower than the industry average of 4.11 [10]